Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.

Backeljauw PF, Underwood LE

The Journal of clinical endocrinology and metabolism1 Apr 2001Cited by 62 (Europe PMC)

PMID11297575DOI10.1210/jcem.86.4.7381PepBankPUB-11297575

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, mean height velocity in years 3--6 of IGF-I treatment (5.4, 5.5, 5.2, and 4.8 cm/yr) stayed slightly below the first two years.
In plain wordsIn children with GH insensitivity, growth speed in years 3--6 of IGF-I treatment stayed slightly below the first two years.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedLater height velocity
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Measurements
Mean height velocity
5.4 cm/yr
year 3
Mean height velocity
5.5 cm/yr
year 4
Mean height velocity
5.2 cm/yr
year 5
Mean height velocity
4.8 cm/yr
year 6
Mean height velocity
9.3 cm/yr
first year of treatment, prior reported comparator for years 3--6
Mean height velocity
6.2 cm/yr
second year of treatment, prior reported comparator for years 3--6
Source sentences
Summary
HV remained slightly below this during the subsequent years (mean HV: 5.4, 5.5, 5.2, and 4.8 cm/yr during years 3--6).
Summary
We previously reported that height velocity (HV) improved with treatment (from mean pretreatment HV of 4.0 cm/yr), to 9.3 cm/yr for the first year and 6.2 cm/yr for the second year.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757501
02HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, height SD score improved from -5.6 before IGF-I to -4.2 after 6 yr.
In plain wordsIn children with GH insensitivity, height scores improved from baseline during IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseHeight SD score
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Measurements
Mean height SD score
−5.6 SD score
before therapy
Mean height SD score
−4.5 SD score
after 2 yr of therapy
Mean height SD score
−4.4 SD score
after 4 yr of therapy
Mean height SD score
−4.2 SD score
after 6 yr of therapy
Source sentences
Summary
Mean height SD score before therapy was -5.6; and it improved to -4.5, -4.4, and -4.2 after 2, 4, and 6 yr of therapy, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757502
03HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, IGF-I treatment accompanied body weight gain.
In plain wordsIn children with GH insensitivity, body weight increased during IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBody weight
Study
n = 8
Outcome group
Body weight · Metabolic and weight
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
Treatment was accompanied by gain in body weight and fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757503
04HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, IGF-I treatment accompanied fat gain.
In plain wordsIn children with GH insensitivity, body fat increased during IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBody fat
Study
n = 8
Outcome group
Body composition · Metabolic and weight
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
Treatment was accompanied by gain in body weight and fat.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757504
05HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, spleen growth was rapid during the first 2--3 yr of IGF-I treatment.
In plain wordsIn children with GH insensitivity, the spleen grew rapidly during early IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSpleen growth
Study
n = 8
Outcome group
Body composition · Immune and inflammation
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
The growth of spleen and kidneys (determined by ultrasound) was rapid in the first 2--3 yr of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757507
06HumanNon-randomized trialEfficacy outcome
In children with GH insensitivity, kidney growth was rapid during the first 2--3 yr of IGF-I treatment.
In plain wordsIn children with GH insensitivity, kidneys grew rapidly during early IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseKidney growth
Study
n = 8
Outcome group
Body composition · Kidney and urinary
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
The growth of spleen and kidneys (determined by ultrasound) was rapid in the first 2--3 yr of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757508
07HumanNon-randomized trialEfficacy outcome
In children receiving IGF-I, six had renal length for height more than 2 SD above the mean at 6--7 yr.
In plain wordsIn children receiving IGF-I, several had kidneys larger than expected for their height during later treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseRenal length for height
Study
n = 8
Outcome group
Kidney function · Kidney and urinary
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6--7 yrAs given in this study (human).
Measurements
Patients with renal length for height more than 2 SD above the mean
6 patients
at 6--7 yr of treatment
Source sentences
Summary
More age- appropriate growth ensued, but six patients had a renal length for height more than 2 SD above the mean at 6--7 yr of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757510
08HumanNon-randomized trialSafety outcome
In children with GH insensitivity receiving IGF-I, no major adverse biochemical profile changes were observed.
In plain wordsIn children with GH insensitivity receiving IGF-I, no major harmful biochemical changes were observed.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableBiochemical profile changes
Study
n = 8
Outcome group
Adverse events · Whole body
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
No major adverse changes in biochemical profile were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757511
09HumanNon-randomized trialEfficacy outcome
In prepubertal children with GH insensitivity receiving IGF-I, bone age advanced normally.
In plain wordsIn prepubertal children with GH insensitivity receiving IGF-I, bone age advanced normally.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicablePrepubertal bone age
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
Bone age advanced normally in the prepubertal patients, but it advanced more rapidly during the latter years of treatment in those patients undergoing pubertal changes.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757505
10HumanNon-randomized trialEfficacy outcome
In children undergoing puberty during IGF-I treatment, bone age advanced more rapidly during later years.
In plain wordsIn children undergoing puberty during IGF-I treatment, bone age advanced faster during later years.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePubertal bone age
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
Bone age advanced normally in the prepubertal patients, but it advanced more rapidly during the latter years of treatment in those patients undergoing pubertal changes.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757506
11HumanNon-randomized trialSafety outcome
In younger children receiving IGF-I, hypoglycemia occurred early and abated with continued treatment.
In plain wordsIn younger children receiving IGF-I, low blood sugar occurred early and decreased with continued treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
80--120 microg/kg twice daily · subcutaneous · 6.5--7.5 yrAs given in this study (human).
Source sentences
Summary
IGF-I-related hypoglycemia occurred early in treatment with the younger patients, but this problem abated as treatment was continued.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80--120 microg/kg sc twice daily) for 6.5--7.5 yr.
Report a problemFND-1129757512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.